Renhong Sun

机构：NuVue Therapeutics (United States), China State Construction Engineering (China), Shanghai Construction Group (China), China Construction Eighth Engineering Division (China) · ORCID：0000-0003-2891-0551

发表论文 42 篇 · 总被引 755 次 · h-index 13

代表论文

• The structural diversity of psychedelic drug actions revealed (2025 · Nature Communications · 被引 34)
• Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement (2023 · Cell · 被引 18)
• Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia (2024 · Cancer Research · 被引 15)
• Discovery of the first-in-class DOT1L PROTAC degrader (2025 · European Journal of Medicinal Chemistry · 被引 11)
• Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader (2024 · Cell Death and Disease · 被引 11)
• NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers (2024 · Cell chemical biology · 被引 11)